Astellas' eyes filings for menopause drug fezolinetant after...

Astellas looks to be in pole position to bring a new non-hormonal therapy for symptoms of menopause to market, after its candidate fezolinetant cleared a phase 3 safety study.

FDA clears Myovant's relugolix for uterine fibroids, setting...

Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with ut

Pfizer/Myovant take relugolix contraceptive combination pill...

Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of a contraceptive combination tablet. 

What can we learn from women’s health data?

Analysing real-world health data could help overcome the bias towards men in traditional medical research, says Sensyne Health's Dr Lucy Mackillop.

VivoPlex raises funding to develop intra-uterine sensor

VivoPlex, a UK based firm specialising in fertility and women’s health, has raised £3.9m to develop an intra-uterine sensor system and generate clinical data that could be used for European

Hormonal drug shortages in UK ‘harming women’, say doctors